Aspirin prescribing pattern and guidelines-adherence evaluation for primary prevention of cardiovascular diseases at a teaching hospital

Antithrombotic Trialists, 2009, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet, 373, 1849, 10.1016/S0140-6736(09)60503-1 Akil, 2011, Relationships between obesity and cardiovascular diseases in four southern states and Colorado, J. Health Care Poor. Underserved., 22, 61, 10.1353/hpu.2011.0166 Arboix, 2015, Cardiovascular risk factors for acute stroke: Risk profiles in the different subtypes of ischemic stroke, World J. Clin. Cases, 3, 418, 10.12998/wjcc.v3.i5.418 Arnett, 2019, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines, Circulation, 140, e596 Bartolucci, 2011, Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin, Am. J. Cardiol., 107, 1796, 10.1016/j.amjcard.2011.02.325 Bibbins-Domingo, K., Force, U.S.P.S.T., 2016. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 164, 836-845. De Berardis, 2012, Association of aspirin use with major bleeding in patients with and without diabetes, JAMA-J. Am. Med. Assoc., 307, 2286, 10.1001/jama.2012.5034 Eckel, R.H., Jakicic, J.M., Ard, J.D., de Jesus, J.M., Houston Miller, N., Hubbard, V.S., Lee, I.M., Lichtenstein, A.H., Loria, C.M., Millen, B.E., Nonas, C.A., Sacks, F.M., Smith, S.C., Jr., Svetkey, L.P., Wadden, T.A., Yanovski, S.Z., American College of Cardiology/American Heart Association Task Force on Practice, G., 2014. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63, 2960-2984. Fiscella, 2015, Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?, J. Gen. Intern. Med., 30, 155, 10.1007/s11606-014-2985-8 Fuster, 2011, Aspirin: a historical and contemporary therapeutic overview, Circulation, 123, 768, 10.1161/CIRCULATIONAHA.110.963843 García Rodríguez, 2016, Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies, PLoS ONE, 11, e0160046, 10.1371/journal.pone.0160046 Gaziano, 2018, Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial, Lancet, 392, 1036, 10.1016/S0140-6736(18)31924-X Halvorsen, 2014, Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis, J. Am. Coll. Cardiol., 64, 319, 10.1016/j.jacc.2014.03.049 Ittaman, S.V., VanWormer, J.J., Rezkalla, S.H., 2014. The role of aspirin in the prevention of cardiovascular disease. Clin Med Res 12, 147-154. Li, 2020, Effects of aspirin on the gastrointestinal tract: pros vs. cons, Oncol Lett, 20, 2567, 10.3892/ol.2020.11817 Lou, 2016, Effects of low-dose aspirin in subjects with dyslipidemia, Lipids Health Dis, 15, 106, 10.1186/s12944-016-0274-8 Lugo, 2014, Regular use of aspirin for cardiovascular disease prevention in Italy, Prev. Med., 63, 48, 10.1016/j.ypmed.2014.03.005 McNeil, 2018, Effect of aspirin on cardiovascular events and bleeding in the healthy elderly, N Engl. J. Med., 2018, 1509, 10.1056/NEJMoa1805819 Members:, A.T.F., Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, W.M.M., Albus, C., Benlian, P., Boysen, G., Cifkova, R., Deaton, C., Ebrahim, S., Fisher, M., Germano, G., Hobbs, R., Hoes, A., Karadeniz, S., Mezzani, A., Prescott, E., Ryden, L., Scherer, M., Syvänne, M., Scholte Op Reimer, W.J., Vrints, C., Wood, D., Zamorano, J.L., Zannad, F., guidelines, O.e.w.c.t.p.o.t., Cooney, M.T., Guidelines, E.C.f.P., Bax, J., Baumgartner, H., Ceconi, C., Dean, V., Deaton, C., Fagard, R., Funck-Brentano, C., Hasdai, D., Hoes, A., Kirchhof, P., Knuuti, J., Kolh, P., McDonagh, T., Moulin, C., Popescu, B.A., Reiner, Ž., Sechtem, U., Sirnes, P.A., Tendera, M., Torbicki, A., Vahanian, A., Windecker, S., Reviewers, D., Funck-Brentano, C., Sirnes, P.A., Aboyans, V., Ezquerra, E.A., Baigent, C., Brotons, C., Burell, G., Ceriello, A., De Sutter, J., Deckers, J., Del Prato, S., Diener, H.C., Fitzsimons, D., Fras, Z., Hambrecht, R., Jankowski, P., Keil, U., Kirby, M., Larsen, M.L., Mancia, G., Manolis, A.J., McMurray, J., Pająk, A., Parkhomenko, A., Rallidis, L., Rigo, F., Rocha, E., Ruilope, L.M., van der Velde, E., Vanuzzo, D., Viigimaa, M., Volpe, M., Wiklund, O., Wolpert, C., 2012. ‘European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)’ The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). [Eur Heart J 2012; 33:1635–1701, doi: 10.1093/eurheartj/ehs092]. European Heart Journal 33, 2126-2126. Naderi, 2012, Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients, Am. J. Med., 125, 882, 10.1016/j.amjmed.2011.12.013 Nemerovski, 2012, Aspirin for primary prevention of cardiovascular disease events, Pharmacotherapy, 32, 1020, 10.1002/phar.1127 Patrono, 2017, Antiplatelet agents for the treatment and prevention of coronary atherothrombosis, J. Am. Coll. Cardiol., 70, 1760, 10.1016/j.jacc.2017.08.037 Patrono, 2019, Role of aspirin in primary prevention of cardiovascular disease, Nat. Rev. Cardiol., 16, 675, 10.1038/s41569-019-0225-y Patti, 2019, Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs, Nat. Rev. Cardiol., 16, 113, 10.1038/s41569-018-0080-2 Pearson, 2002, Circulation, 106, 388, 10.1161/01.CIR.0000020190.45892.75 Piepoli, M.F., Hoes, A.W., Agewall, S., Albus, C., Brotons, C., Catapano, A.L., Cooney, M.T., Corra, U., Cosyns, B., Deaton, C., Graham, I., Hall, M.S., Hobbs, F.D.R., Lochen, M.L., Lollgen, H., Marques-Vidal, P., Perk, J., Prescott, E., Redon, J., Richter, D.J., Sattar, N., Smulders, Y., Tiberi, M., van der Worp, H.B., van Dis, I., Verschuren, W.M.M., Binno, S., Group, E.S.C.S.D., 2016. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37, 2315-2381. Pignone, 2010, Circulation, 121, 2694, 10.1161/CIR.0b013e3181e3b133 Raber, 2019, The rise and fall of aspirin in the primary prevention of cardiovascular disease, Lancet, 393, 2155, 10.1016/S0140-6736(19)30541-0 Rodés-Cabau, 2015, Effect of clopidogrel and aspirin vs aspirin alone on migraine headaches after transcatheter atrial septal defect closure: the CANOA randomized clinical trial, JAMA, 314, 2147, 10.1001/jama.2015.13919 Rothwell, 2011, Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials, Lancet, 377, 31, 10.1016/S0140-6736(10)62110-1 Seidu, 2019, Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials, Cardiovasc Diabetol, 18, 70, 10.1186/s12933-019-0875-4 Singh, 2014, Chemopreventive strategies in hepatocellular carcinoma, Nat. Rev. Gastroenterol. Hepatol., 11, 45, 10.1038/nrgastro.2013.143 Vandvik, P.O., Lincoff, A.M., Gore, J.M., Gutterman, D.D., Sonnenberg, F.A., Alonso-Coello, P., Akl, E.A., Lansberg, M.G., Guyatt, G.H., Spencer, F.A., 2012. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141, e637S-e668S. VanWormer, 2012, Aspirin for primary prevention of CVD: are the right people using it?, J. Fam. Pract., 61, 525 VanWormer, 2014, Aspirin overutilization for the primary prevention of cardiovascular disease, Clin. Epidemiol., 6, 433, 10.2147/CLEP.S72032 Wang, 2020, The risk of gastrointestinal hemorrhage in low-dose aspirin users with diabetes mellitus: systematic review and meta-analysis, Gastroenterol. Res. Pract., 2020, 1 Xing, 2019, Aspirin for primary prevention of cardiovascular disease in diabetes, J. Diabetes Investig., 10, 899, 10.1111/jdi.13006 Zheng, 2019, Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis, JAMA, 321, 277, 10.1001/jama.2018.20578